AI made execution free. Knowing first is the whole game now.
The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.
Trusted by
Ligand Pharmaceuticals Acquires Royalty Rights from Sydnexis
Acquiring Company
Ligand Pharmaceuticals Incorporated
Acquired Company
Sydnexis
San DiegoDel MarBiotechnologyHealthcareHealth CarePharmaceuticalBiopharmaBiotechnologyHealthcareHealth CareScience And EngineeringDescription
On September 22, 2026, Ligand Pharmaceuticals announced the acquisition of royalty and milestone payment rights related to Santen Pharmaceutical’s Ryjunea from Sydnexis Inc. The transaction was valued at $23 million upfront. This acquisition enhances Ligand's portfolio in the pharmaceutical space. Additional details regarding the transaction were provided in the press release issued by Ligand.
Fundz sees it the moment Ligand Pharmaceuticals Incorporated makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired Sydnexis?
Sydnexis was acquired by Ligand Pharmaceuticals Incorporated, based in San Diego. The deal was reported on September 22, 2026. Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand Pharmaceuticals Incorporated is publicly traded (LGND) and operates in Biotechnology.
When did Ligand Pharmaceuticals Incorporated acquire Sydnexis?
Ligand Pharmaceuticals Incorporated's acquisition of Sydnexis was reported on September 22, 2026. On September 22, 2026, Ligand Pharmaceuticals announced the acquisition of royalty and milestone payment rights related to Santen Pharmaceutical’s Ryjunea from Sydnexis Inc. The transaction was valued at $23 million upfront. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Sydnexis do?
Sydnexis is a San Diego based clinical stage pharmaceutical company currently in the middle of a pivotal Phase 3 study, focused on the development of a novel proprietary formulation of low dose atropine for the treatment of myopia. It is privately held, operating in Biotechnology, and is based in Del Mar.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.
5 screens from a live account. No signup.